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Background. A positive association between genetic polymorphism and asthma may not be extrapolated from one ethnic group
to another based on intra- and interethnic allelic and genotype frequencies diﬀerences. Objective. We assessed whether polymor-
phisms of GST genes (GSTM1, GSTT1, and GSTP1) are associated with asthma and atopy among Tunisian children. Methods.
112 unrelated healthy individuals and 105 asthmatic (73 atopic and 32 nonatopic) children were studied. Genotyping the poly-
morphisms in the GSTT1 and GSTM1 genes was performed using the multiplex PCR. The GSTP1 ILe105Val polymorphism
was determined using PCR-RFLP. Results. GSTM1 null genotype was signiﬁcantly associated with the increased risk of asthma
(P = .002). Asthmatic children had a higher prevalence of the GSTP1Ile105 allele than the control group (43.8% and 33.5%,
respectively; P = .002). Also, the presence of the GSTP1 homozygote Val/Val was less common in subjects with asthma than in
control group. We have found that GSTT1 null genotype (GSTT1 ∗0/∗0) was signiﬁcantly associated with atopy (P = .008). Con-
clusion. Polymorphisms within genes of the GST superfamily were associated with risk of asthma and atopy in Tunisia.
Copyright © 2007 Chelbi Hanene et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Asthma is a chronic disease characterized by reversible air-
ﬂow obstruction and airway inﬂammation that aﬀect many
people. There is evidence that a genetic predisposition may
also alter the capability of the airway to protect itself against
inhaled toxic substances from the environment [1, 2].
Several candidate genes were implicated in the develop-
ment of atopy and asthma. It has been reported that preva-
lence of these candidate genes can vary considerably by eth-
nicity [3, 4]. Furthermore, data from given studies suggest
that a positive association between genetic polymorphism
and asthma or atopy may not be extrapolated from one eth-
nic group to another based on intra- and interethnic allelic
and genotype frequencies diﬀerence.
In North Africa, and especially in Tunisia, research data
onthissubjectisabsent.Thatiswhyweselectedamongasth-
matic candidate genes three genes that have been known to
manifest remarkable inter- and intraethnic diﬀerences [5].
These genes are GSTT1, GSTM1,a n dGSTP1, which are
the code names for enzymes belonging to the glutathione
S-transferase (GST) super family. In humans, GSTs repre-
sent a large and diverse super family of enzymes, with at
least 13 GST e n z y m e sb e l o n g i n gt oﬁ v ed i ﬀerent families:
mu, theta, alpha, pi, and gamma. The GSTM1, GSTT1,a n d
GSTP1 belong, respectively, to the GSTmu, GSTtheta, and
GSTpi categories of enzymes. GSTs are known to play an
important role in the functioning of antioxidant defences
through reactive oxygen species (ROS) metabolism, in the
repairing of damaged ROS and in the detoxiﬁcation of sev-
eral xenobiotics such as carcinogens found in tobacco smok-
ing [6, 7]. The role played by GSTs may be especially im-
portant in response to oxidative stress [6, 8]. Common
homozygote deletion polymorphisms of the GSTM1 and
GSTT1 genes, as well as the GSTP1Ile105 polymorphism,
have been known to abolish enzymes activity and increase
susceptibility to oxidative stress [6, 8]. Studies have so far
reported contradictory results regarding any association be-
tween GST gene polymorphisms and asthma and/or atopy.
Infact,somehavereportedthepresenceofanassociationbe-
tween GSTP1VAL105Ile polymorphisms and bronchial hy-
per responsiveness (BHR), asthma and atopy [9–16]. How-
ever, other studies have found no such evidence of any asso-
ciation between polymorphism and asthma or atopy [17]. In
several studies, null alleles in the GSTT1 and GSTM1 genes
(GSTT1∗0a n dG S T M 1 ∗0) were associated with childhood
asthma [10, 11, 18, 19] but this ﬁnding was contradicted in
other studies [17].2 Mediators of Inﬂammation
Although there is a high incidence of asthmatic diseases
in Tunisia, no data has been reported in this country. In
this study we assess whether polymorphisms of GST genes
previously found to be associated with asthma and atopy in
Caucasian and Asiatic subjects are also to be associated with
asthma and atopy in Tunisian children.
2. SUBJECTS AND METHODS
2.1. Studysubjects
Asthmatic children’s histories were recorded using stan-
dard questionnaire categories: age, sex, exposure to tobacco
smoke, and family history of asthma and allergy.
A total of 105 asthmatic children ranging from ages of 5
to16years(mean11.5)wereenrolledinthisstudyalongwith
112 control individuals (aged 5 to 16 years, mean 9.5). None
had any recent illnesses requiring treatment and no history
of chronic diseases. All lived in the countryside near Tunis,
in a town called Ariana. This region is generally considered
to be representative of the general Tunisian population. Our
national ethics committee approved the study.
2.2. TotalIgEandPricktestassays
Atopy was deﬁned by the skin sensitivity to speciﬁc allergens
(skinreactionwithameanwealdiameter ≥3mmlargerthan
that produced with one or more antigens in the presence of
positive histamine control and a negative uncoated control)
and by measurement of the total IgE level. Positive values
were taken to be ≥ 200UI/ml.
Among the 105 asthmatic children there were 73 atopic
and 32 nonatopic children who had negative skin test re-
sponses to common allergens. In our study, asthma is fre-
quentlyrelatedtoaheterogeneousgroupofclinicaldisorders
including rhinitis, sinusitis, and dermatitis. The clinical pro-
ﬁles are shown in Table 1.
2.3. DNAisolation
The genomic DNA for genotyping was isolated from 10ml
of peripheral blood lymphocytes which were collected, using
a salting-out DNA extraction procedure [19], in an EDTA
containing a vacutainer.
2.4. GSTM1andGSTT1genotypes
The GSTM1 and GSTT1 null genotypes were detected
using a multiplex PCR method [20]. Brieﬂy, 100ng of
DNA were ampliﬁed in a-50ul multiplex reaction mix-
ture containing 0.90pmol of each of the following GSTM1
primers (GSTM1-F: TTCCTCACTGGTCCTCACATCT-
C and GSTM1-R: TCACCGGATCATGGCCAGCA) and
GSTT1 primers (GSTT1-F: GAACTCCCTGAAAAGCTAA-
AGC and GSTT1-R: GTTGGGCTCAAATATACGGTGG).
As an internal control, the ALBUMIN gene was also am-
pliﬁed with 0.2pmol of each primer (AlbF: GCCCTCTG-
CTAACAAGTCCTAC and AlbR: GCCCTAAAAAGAAAA-
Table 1: The clinical characteristics.
Cases n (%) Controls n (%)
Male 62 (59) 62 (55.3)
Female 43 (41) 50 (44.7)
Sex ratio (female/male) 0.69 0.80
Mean age
(standard deviation) 11.5 (5–16) 9.5 (5–16)
FEV1 (% predicted)∗∗ 96.1±14.2 ND
FVC (%predicted)∗∗∗ 97.4±14.6 ND
Atopic 73 (70.32) 0
Nonatopic 32 (29.68) 112 (100)
Passive smoking n(35) n(22)
Phenotypes
associated
Rhinitis 15 (14.28) 0
Sinusitis 7 (6.66) 0
Dermatitis 5 (4.76) 0
RGO∗ 8 (7.61) 0
Asthma, dermatitis,
and rhinitis 7 (6.66) 0
Asthma, sinusitis,
and rhinitis 5 (4.76) 0
∗RGO: gastro-esophageal reﬂux.
∗∗FEV1: forced expiratory volume in 1second.
∗∗∗FVC: forced vital capacity; ND, not determined.
TCGCCAATC) in a medium consisting of 3.5mM MgCl2,
200uM dNTPs, 5ul 10X PCR buﬀer, and 2U TaqDNA poly-
merase. The PCR protocol included an initial melting tem-
perature of 94◦C (5 minutes) followed by 35 cycles of am-
pliﬁcation (20 seconds at 94◦C, 20 seconds at 64◦C, and 30
second at 72◦C). A ﬁnal 7-minute extension step (72◦C) ter-
minated the process.
The PCR products were analyzed on agarose gels. A frag-
ment of 215pb indicated the presence of GSTM1; a frag-
ment of 480pb indicated the presence of GSTT1;a n da
fragment of 380pb indicated the positive internal control
albumin. The subjects were classiﬁed as either (+), when
at least one specimen of the gene was detected, or (−)
when they showed a null genotype. Heterozygous individ-
uals with GSTM1 (GSTM1+/− and GSTM1+/+) or GSTT1
(GSTT1+/− and GSTT1+/+) were reported to present simi-
lar enzymes activity [21] and expression levels [22]a n dw e r e
pooled together for statistical analysis.
2.4.1. GSTP1genotype
GSTP1 313A→G polymorphism (resulting in Ile105Val at
codon 105) was analyzed by PCR-restriction fragment
length polymorphism (RFLP) analysis [23]. Genomic DNA
(100ng) was used as a DNA template in a total 50µlv o l -
ume reaction. The PCR products were digested in 25µlf o r
2 hours at 37◦C with 5U Alw261. The digested products were
then separated with 3% agarose gel stained with ethidium
bromide. The presence of a-176pb fragment indicated the
wild-type genotype, whereas the 85 and 91pb fragments in-
dicated the homozygous polymorphic genotype. Heterozy-
gous individuals recorded all three types of fragments.Chelbi Hanene et al. 3
Table 2: Association of genotype proﬁle between asthmatics and controls. NS: P value >. 05.
Asthmatics Controls
Gene Chromosomal
location Polymorphisms Genotypes (n = 105) (%) (n = 112) (%) OR 95%
CI
P
value
GSTM1 1p13 Null allele Null 79 70.7 53 50.2 2.35 1.30–4.27 .002
WT 33 29.3 52 49.8
GSTT1 22q11 Null allele Null 42 37.5 31 29.5 1.43 0.78–2.63 NS
WT 70 62.5 74 70.5
GSTP1 11q13 Ile105Val
Ile/Ile 49 43.8 35 34.4 1.32 0.70–2.47 NS
Ile/Val 51 45.5 48 47.1 1.77 0.73–4.35 NS
Val/Val 12 10.7 20 18.6 2.33 0.94–5.87 .04
A(Ile) 149 66.5 118 56.2 1.55 1.03–2.33 .027
G(Val) 75 33.5 92 43.8
Table 3: Association between genotype proﬁle and atopic asthma. NS: P value >. 05.
Atopic asthmatics Nonatopic asthmatics
Gene Chromosomal
location Polymorphisms Genotypes (n = 73) % (n = 32) % OR 95%CI P value
GSTM1 1p13 Null allele Null 37 50.7 13 40.6 —— NS
WT 36 49.3 19 59.4 1.5 0.6–3.80
GSTT1 22q11 Null allele Null 36 49.31 7 21.8 —— .008
WT 37 50.69 25 78.12 3.74 1.23–10.15
GSTP1 11q13 Ile105Val
Ile/Ile 31 42.5 13 43.0 —— —
Ile/Val 34 46.50 12 40.0 0.87 0.31–2.41 NS
Val/Val 08 11.00 07 23.3 1.85 0.49–7.08 NS
A(Ile) 95 65 38 59.4 —— —
G(Val) 51 35 26 40.6 1.27 0.67–2.43 NS
3. STATISTICAL ANALYSIS
Associationanalysisinourcase-controlstudywasperformed
using standard Chi-squared test (Epistat statistical package,
Epi Info Version 6) to detect diﬀerences in genotypes and al-
leles distribution among our groups.
Correction for multiple comparisons was performed,
a n do n l yt h ev a l u eo fc o r r e c t e dP<. 05 was considered to
be signiﬁcant.
4. RESULTS
4.1. Case-controlanalysis
The association between GST genotype and susceptibility
was studied in 105 unrelated asthmatic children residing in
the northern part of Tunisia, using a control group of 112
healthy children.
Table 1 summarizestheclinicalcharacteristicsof subjects
conducted in this study. In total, 35% of asthmatic children
and 22% of nonasthmatic children were passive smokers.
Withanaverageageof11.5(rangingbetween5and16years),
70.32% of the asthmatic children were diagnosed as atopic.
Table 2 summarizes the data found regarding the geno-
type frequencies for the RFLP in the GSTP1 g e n e ,a sw e l la s
the homozygous deletions of the GSTM1 and GSTT1 genes.
Genotype frequencies (GSTP1, GSTM1,a n dGSTT1)w e r e
within the Hardy-Weinberg equilibrium for control popula-
tion.
WefoundthatGSTM1nullgenotypewassigniﬁcantlyas-
sociated with increased risk of asthma (P = .002). Indeed,
the GSTM1 null genotype was present among 70.7% of the
asthmatic children and among 50.2% of the control group.
As for the GSTP1, the homozygote GSTP1 Val/Val geno-
type was less common among the asthmatic patients than
in the control group (10.7% versus 18.6%, P = .04).
Subjects with the GSTP1Val/GSTP1Val genotype registered
a-2.33 fold lower risk of asthma than those with the
GSTP1Ile/Ile genotype (OR = 2.33, 95% CL 0.94–5.87).
Between both study samples, there was a signiﬁcant diﬀer-
ence in the frequency of the GSTP1 alleles (P = .02): asth-
matic children had a higher prevalence of the GSTP1Ile al-
lele than those in the control group (43.8% and 33.5%,
resp.).
ThepresenceoftheGSTT1nullpolymorphismwascom-
p a r e di nb o t hs a m p l eg r o u p s .T h ed i ﬀerence showed to be
nonsigniﬁcant (P>. 05) between controls and asthmatics,
29.5% and 37.5%, respectively, see (Table 2).
4.2. GSTgenesandatopy
Table 3 summarizes the association between GST genes and
atopy.4 Mediators of Inﬂammation
Table 4:ComparisonfrequenciesofGSTM1andGSTT1genepoly-
morphisms in Caucasian control populations.
Country GSTM1 null GSTT1 null Reference
Tunisia 50.33% (105)∗ 29.50% (105) Present
study
Egypt 55.50% (200) 29.50% (300) [24]
United Kingdom 57.80% (1122) 20.50% (922) [5]
Sweden 55.90% (544) 13.00% (423) [5]
France 53.40% (1184) 16.80% (512) [5]
WhiteBrazilians 55.50% (233) 22.30% (233) [25]
Canada 58.00% (90) 22.00% (90) [26]
Spain 54.00% (200) ND [27]
Netherlands 50.40% (419) 22.90% (419) [5]
Germany 53.00% (219) 20.00% (219) [28]
Turkey 51.90% (133) 17.30% (133) [29]
∗ Numbers between brackets represent the sample size; ND, not
determined.
The GSTT1 null genotype (GSTT1∗0/∗0) was signiﬁ-
cantly higher in atopic asthmatic cases than in nonatopic
asthmatic subjects (P = .008). As for the GSTM1, there was
a-1.5 fold increased risk of atopic asthma in individuals with
the GSTM1 null genotype (OR = 1.5; 95% CI, 0.6–3.83), but
this increase was not signiﬁcant. No signiﬁcant associations
have been found between atopy and GSTP1 polymorphism
in present study.
4.3. PolymorphismsofglutathioneS-transferase
M1,T1,andP1inaTunisiancontrolpopulation
Human cytosolic GSTs have been well documented; they are
polymorphic and have ethnic-dependent polymorphism fre-
quencies.Comparedwithresearchcarriedoutinothercoun-
tries, the distribution of the GSTM1 null genotype and the
GSTT1 null among our group of control was found to be,
respectively, 50.2% and 29.5% (Table 4). Their GSTP1 poly-
morphism frequencies for the Ile/Ile genotype registered at
34.4%, at 47.1% for the Ile/Val genotype, and at 18.6% for
the Val/Val genotype (Table 2). The Ile allele frequency for
this particular group was set at 0.562.
5. DISCUSSION
TheglutathioneS-transferase(GST)superfamilyofenzymes
has a vital role in phase II of biotransformation of xenobi-
otics and in protection of cells from reactive oxygen species
(ROS) by its ability to utilize substrates of a wide range of
productsofoxidativestress[6].Oxidativestresswasreported
tobethekeycomponentofinﬂammation.Inﬂammationwas
consideredacharacteristicofasthmadiseasewhenitattacked
airways. So defect in detoxifying ROS may inﬂuence the de-
velopment and severity of asthma.
The results of our works suggest the presence of associ-
ations of GSTM1, T1, and P1 with childhood asthma and
atopy. In comparing asthmatic children to healthy controls
we have demonstrated a signiﬁcant association between sub-
jects lacking GSTM1 activity and asthma (P = .002). Nu-
merous studies have demonstrated a signiﬁcant association
between subjects lacking GSTM1 activity and the risk of de-
veloping a form of lung disease [30–32]. For asthmatics, the
association with GSTM1 null genotype has been reported
in Caucasian population [11, 18, 33, 34] but not in Asiatic
groups [35].
As for the GSTP1, we have also found signiﬁcant diﬀer-
ences between our two study samples regarding the geno-
type frequencies of the GSTP1Ile105Val polymorphisms. In-
deed, asthmatic children have low frequency of GSTP1Val
allele compared with healthy children (P = .002). The de-
f e n s i v er o l eo ft h eGSTP1 in cases of asthma was reported
in several studies [9, 12–15]. It was reported that the pres-
enceofGSTP1Val/Valgenotypeconferredasixfoldlowerrisk
of asthma than did GSTP1Ile/Ile and that the frequency of
GSTP1Val/Val genotype correlated negatively with severity
of airway dysfunction [9]. Aynacioglu et al. [12] have also
reported that the frequency of GSTP1 Val homozygote was
signiﬁcantly lower in the group of patients with asthma than
in the control individuals (3.8% versus 12.1%, P = .01).
On the other hand, a recent study [11] has found that the
GSTP1Val/Valwasmoreprevalentamongasthmaticsubjects
than the control group (22.8% and 7.8%, respectively) and
that subjects with the GSTP1 homozygous Val/Val genotype
had a 3.55-fold increased risk of having atopic asthma com-
pared to nonatopic asthma (OR = 3.55; 95% CI, 1.10–
12.56), see [11]. Although, the GSTP1-derived enzyme con-
tributes more than 90% of GST activity [36], it has been
foundbymanystudies[9,12–15]andconﬁrmedbyourﬁnd-
ing that it protects children against developing asthma dis-
ease. Nevertheless, it has been reported that the Val105 vari-
ant has higher catalytic eﬃciency for polycyclic aromatic hy-
drocarbon diol epoxides but its eﬃciency for 1-chloro-2, 4-
dinitrobenzene is lower compared to the Ile105 variant [37].
Therefore, it seems to be possible that GSTP1 plays a role in
asthma disease by modulation of ROS production.
In this study, for GSTT1 null genotype, signiﬁcant as-
sociation was found between atopic asthmatic children and
nonatopic asthmatic children (P = .008), see (Table 2).
While our ﬁndings are substantiated by several studies on
Caucasians populations [11, 33], other studies were unable
to establish this association [17, 18, 34, 38]. Several stud-
ies have suggested that individuals with the GSTT1∗0/∗0
(GSTT1null)genotypemaybemoresusceptibletogenotoxic
damage and lung diseases than individuals with the GSTT1
gene [30, 39].
Contradictory results were found in regards to GSTT1,
GSTP1,a n dGSTM1 [11, 17, 34, 35, 39]; ethnicity is the most
important reason for these diﬀerences. That is why we have
taken into consideration inter- and intraethnic characteris-
tics in analyzing our ﬁndings.
In control populations with intra- and interethnic diﬀer-
ences, frequent genetic deletion polymorphisms of GSTM1
(GSTM1∗0/∗0) and GSTT1 (GSTT1∗0/∗0) have been re-
ported[5].ThedistributionoftheGSTM1nullgenotypeand
GSTT1 null of our healthy control sample was found to be
50.2% and 29.5%, respectively, see (Table 2).Chelbi Hanene et al. 5
The frequency of GSTM1 null genotype in our healthy
controls (50.2%) seems to be within the frequency range re-
ported for the Caucasian populations (Table 4). In fact, the
GSTM1 deletion frequencies range, respectively, from 50.4%
to 58.00%, 49% to 63%, and 20% to 33% in Caucasian, Asi-
atic, and African control groups [5].
Regarding GSTT1 null type, the frequency of deletion
genotype in our Tunisian control group is set at 29.5%. Like
the Egyptian population, Tunisia has a slightly higher fre-
quency than that registered by Caucasian Europeans (be-
tween 13% and 22.3%) and Africans (between 19% and
26%).ThefrequencyofthedeletiongenotypeintheTunisian
population is closer to that of the Caucasian Americans
(10%–36%) and is considerably lower than that reported for
the Asiatic populations (45% to 53%).
In conclusion, we have demonstrated that polymor-
phisms of GST genes previously found to be associated with
asthma and atopy in Caucasian and Asiatic subjects are
also associated with asthma and atopy in Tunisian children.
Therefore,GST genotypesmaybeusefulinordertooptimize
future treatment of asthma in the cases of patients with a risk
proﬁle.
ABBREVIATIONS
GST: Glutathione-S-transferase
OR: Odds ratio
ROS: Reactive oxygen species
PCR-RFLP: Restriction length polymorphism
PCR: Polymerase chain reaction
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